Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) is reporting second quarter earnings results on Monday 10th August 2020, before market open.
The consensus estimates from Thomson Reuters are loss of $ 0.73 per share.
For the full year, analysts predict revenues of $ 13.49 million, while looking forward to loss of $ 2.99 per share.
Previous Quarter Performance
Xeris Pharmaceuticals, Inc. communicated loss for the first quarter of $ 0.89 per share, from the revenue of $ 1.79 million. The quarterly revenues extended 616.00 percent compared with the same quarter last year. The consensus estimates are loss of $ 0.89 per share from $ 1.43 million in revenue. The bottom line results street analysts by $ 0 or , at the same time, top line results outshined analysts by $ 0.36 million or 25.17 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Xeris Pharmaceuticals, Inc.
Stock Performance
According to the previous trading day, closing price of XERS was $ 3.35, representing a 135.92 % increase from the 52 week low of $ 1.42 and a 73.2 % decrease over the 52 week high of $ 12.50.
The company has a market capital of $ 154.46 million and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”XERS” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Xeris Pharmaceuticals, Inc. will be hosting a conference call at 8:30 AM eastern time on 10th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.xerispharma.com
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The companys lead product candidate is Gvoke HypoPen, which has completed Phase III clinical trials for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes.
